Advaxis, Inc. Release: Fifteen Percent of ADXS11-001 Treated Cervix Cancer Patients Still Alive Three Years after Initial Dosing

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.